The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...
Suggested Citation: "Appendix C: Commissioned Paper: Topical Dosage Form Development and Evaluation." National Academies of Sciences, Engineering, and Medicine. 2020. Compounded Topical Pain Creams: ...
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonaltopical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results